Cargando…

CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study

Our previous studies revealed that the level of activated circulating endothelial cells (aCECs) was correlated with the progression‐free survival (PFS) in antiangiogenesis therapy. Anlotinib displayed affirmatory efficacies in several clinical trials of non‐small‐cell lung cancer (NSCLC). To find a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhujun, Wang, Jing, Meng, Zhaoting, Wang, Xinyue, Zhang, Cuicui, Qin, Tingting, Chen, Jinliang, Jiang, Xiangli, Wang, Liuchun, Lin, Li, Zhang, Xiaoling, Chen, Peng, Huang, Chun, Jiang, Richeng, Li, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051165/ https://www.ncbi.nlm.nih.gov/pubmed/29856135 http://dx.doi.org/10.1002/cam4.1584

Ejemplares similares

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study
por: Zhang, Linlin, et al.
Publicado: (2023)

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
por: Cheng, Ying, et al.
Publicado: (2020)

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303
por: Si, Xiaoyan, et al.
Publicado: (2019)

Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer
por: Zhang, Cuicui, et al.
Publicado: (2022)

Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial
por: Shi, Jianhua, et al.
Publicado: (2021)

The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study
por: Zhao, Yizhuo, et al.
Publicado: (2022)

Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements
por: Li, Shouying, et al.
Publicado: (2019)

Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
por: Chen, Qing, et al.
Publicado: (2021)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
por: Wu, Di, et al.
Publicado: (2020)

Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review
por: Zuo, Ran, et al.
Publicado: (2020)

Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial
por: Cheng, Ying, et al.
Publicado: (2021)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level
por: Cao, Lianjing, et al.
Publicado: (2017)

EHMTI-0303. Treatment of medication overuse headache
por: Madsen, SK, et al.
Publicado: (2014)

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
por: Liu, Shaochuan, et al.
Publicado: (2020)

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
por: Zhou, Yongjian, et al.
Publicado: (2023)

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
por: Liu, Zhiyong, et al.
Publicado: (2021)

Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer
por: Jiang, Richeng, et al.
Publicado: (2016)

P03.03. Facebook use and professionalism among CAM students
por: Hinck, G, et al.
Publicado: (2012)

PA03.03. Effect of manjishtadi lepa in management of ankle sprain
por: Patil, S Suraj, et al.
Publicado: (2013)

OR0303 Syndecans Enhance Ghrelin-Induced GHSR1a Signaling
por: Prins, Karina, et al.
Publicado: (2023)

Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
por: Su, Yudong, et al.
Publicado: (2022)

microRNA-1298 inhibits the malignant behaviors of breast cancer cells via targeting ADAM9
por: Chen, Weili, et al.
Publicado: (2020)

C644‐0303, a small‐molecule inhibitor of the Wnt/β‐catenin pathway, suppresses colorectal cancer growth
por: Yan, Yu, et al.
Publicado: (2021)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019)

EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes
por: Yudong, Su, et al.
Publicado: (2018)

Sentinel lymph node biopsy in early stage cervical cancer: A meta‐analysis
por: Zhang, Xinyue, et al.
Publicado: (2020)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
por: Wang, Zhi‐Ming, et al.
Publicado: (2020)

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib
por: Qin, Boyu, et al.
Publicado: (2021)

Revealing the clinical significance and prognostic value of small nucleolar RNA SNORD31 in hepatocellular carcinoma
por: Ding, Yuan, et al.
Publicado: (2020)

Association of Nuclear PIM1 Expression with Lymph Node Metastasis and Poor Prognosis in Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma
por: Jiang, Richeng, et al.
Publicado: (2016)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
por: Zhou, Jun, et al.
Publicado: (2023)

Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling
por: Qin, Tingting, et al.
Publicado: (2020)

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
por: Huang, Jing, et al.
Publicado: (2021)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
por: Wang, Jing, et al.
Publicado: (2023)

Higher miR‐543 levels correlate with lower STK31 expression and longer pancreatic cancer survival
por: Yuan, Weizhong, et al.
Publicado: (2020)

Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells
por: Jiang, Yuelong, et al.
Publicado: (2022)

Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling
por: Zhang, Xiaoling, et al.
Publicado: (2020)

Uncovering and Engineering a Mini-Regulatory Network of the TetR-Family Regulator SACE_0303 for Yield Improvement of Erythromycin in Saccharopolyspora erythraea
por: Liu, Ying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ivmn9naqlt8kkoeml46d37jq81